The AI drug discovery project consisted of Insilico Medicine, the University of Toronto’s Acceleration Consortium and researchers including Nobel laureate Michael Levitt. The team applied AlphaFold to Insilico’s end-to-end AI-powered drug discovery platform, Pharma.AI. With the integration of the biocomputational engine PandaOmics and the generative chemistry engine Chemistry42, the AI drug discovery project identified a novel treatment pathway for HCC and developed a potent inhibitor based on a predicted protein structure.…
Using AlphaFold, Insilico Medicine produces AI drug discovery in record time
The AI drug discovery project consisted of Insilico Medicine, the University of Toronto’s Acceleration Consortium and researchers including Nobel laureate Michael Levitt. The team applied AlphaFold to Insilico’s end-to-end AI-powered drug discovery platform, Pharma.AI. With the integration of the biocomputational engine PandaOmics and the generative chemistry engine Chemistry42, the AI drug discovery project identified a novel treatment pathway for HCC and developed a potent inhibitor based on a predicted protein structure.…